一品红：全资子公司获盐酸克林霉素棕榈酸酯颗粒注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Clindamycin Palmitate Granules, indicating a significant advancement in its pharmaceutical offerings [1] Group 1: Product Approval - The full subsidiary of the company, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for Clindamycin Palmitate Granules [1] - Clindamycin is indicated for severe infections caused by sensitive anaerobic bacteria, as well as infections caused by sensitive strains of Streptococcus, Pneumococcus, and Staphylococcus [1] - The product is specifically indicated for patients who are allergic to penicillin or those deemed unsuitable for penicillin by a physician, with clear dosage instructions for pediatric use included in the product's labeling [1]